相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacokinetic issues for antibiotics in the critically ill patient
Jason A. Roberts et al.
CRITICAL CARE MEDICINE (2009)
Incidence and outcomes of acute kidney injury in intensive care units: A Veterans Administration study
Charuhas V. Thakar et al.
CRITICAL CARE MEDICINE (2009)
Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients
Christopher John Kirwan et al.
INTENSIVE CARE MEDICINE (2009)
ESRD Impairs Nonrenal Clearance of Fexofenadine but not Midazolam
Thomas D. Nolin et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008
R. Phillip Dellinger et al.
CRITICAL CARE MEDICINE (2008)
Principal Component Analysis of CYP2C9 and CYP3A4 Probe Substrate/Inhibitor Panels
Abhinav Nath et al.
DRUG METABOLISM AND DISPOSITION (2008)
Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions
Scott R. Penzak et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients
Sean M. Bagshaw et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury
A. Mary Vilay et al.
CRITICAL CARE (2008)
Pharmacokinetics of fexofenadine enantiomers in healthy subjects
Masatomo Miura et al.
CHIRALITY (2007)
Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units
Sean M. Bagshaw et al.
CRITICAL CARE (2007)
The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity
Daniel Kurnik et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers
Emmanuel Krupka et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity
A Westlind-Johnsson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Drug-associated disease: Cytochrome P450 interactions
HJ Mann
CRITICAL CARE CLINICS (2006)
Pharmacogenetics, drug-metabolizing enzymes, and clinical practice
Sharon J. Gardiner et al.
PHARMACOLOGICAL REVIEWS (2006)
Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam
HN Chaobal et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage
RA Wilke et al.
PHARMACOGENETICS AND GENOMICS (2005)
Tramadol as a new probe for cytochrome P450 2D6 phenotyping: A population study
RS Pedersen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450
J Michaud et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Tacrolimus pharmacogenetics: The CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and south Asians
IAM MacPhee et al.
TRANSPLANTATION (2005)
Lipid-lowering response to statins is affected by CYP3A5 polymorphism
KT Kivistö et al.
PHARMACOGENETICS (2004)
Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis
ED Kharasch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation
IAM MacPhee et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Moving towards individualized medicine with pharmacogenomics
WE Evans et al.
NATURE (2004)
Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women
MD Floyd et al.
PHARMACOGENETICS (2003)
The measurement of liver blood flow: A review of experimental and clinical methods
PKH Chow et al.
JOURNAL OF SURGICAL RESEARCH (2003)
Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease
TC Dowling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Genomic medicine - Inheritance and drug response.
R Weinshilboum
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Significant drug-metabolizing role for CYP3A5?
JA Williams et al.
DRUG METABOLISM AND DISPOSITION (2003)
The effect of chronic renal failure on hepatic drug metabolism and drug disposition
AW Dreisbach et al.
SEMINARS IN DIALYSIS (2003)
Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?
S Wanwimolruk et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Down-regulation of hepatic cytochrome P450 in chronic renal failure:: role of uremic mediators
C Guévin et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin
MF Paine et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism
YS Lin et al.
MOLECULAR PHARMACOLOGY (2002)
Downregulation of intestinal cytochrome P450 in chronic renal failure
FA Leblond et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2002)
Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers
EL Swart et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration
YS Lin et al.
PHARMACOGENETICS (2001)
The genetic determinants of the CYP3A5 polymorphism
E Hustert et al.
PHARMACOGENETICS (2001)
Early goal-directed therapy in the treatment of severe sepsis and septic shock.
E Rivers et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons
C Finta et al.
GENE (2000)
Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans
A Paulussen et al.
PHARMACOGENETICS (2000)
分享论文
